Reviews on remdesivir in Covid-19 treatment
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
Tag: Captisol
Renal and liver injury following the treatment of covid-19 by remdesivir
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Sedor Pharmaceuticals, LLC (Sedor) announced on November 9, 2020 that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT
Remdesivir dry powder inhalation formulation, pharmacokinetic study in hamsters
Currently, remdesivir is only available as a lyophilized powder for reconstitution and intravenous53 infusion and concentrate solution for dilution and
Use of sulfobutylether beta cyclodextrin for preparing ceramics
A very few patent applications may trace back prior art disclosure to the Neolithic Age (from 10000 – 4500 BC)
Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it
Top-line final data from CD-enabled Cantrixil Phase I study confirms prior positive efficacy and safety signals
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
Combined therapy (remdesivir, dexamethasone and monoclonal antibodies) for the treatment of President Trump
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital